SillaJen, Inc. is a high-risk Pharmaceuticals company from South Korea that specializes in developing innovative cancer treatment cells. The company, along with its subsidiary SillaJen Biotherapeutics, Inc, offers cutting-edge oncolytic virus therapies like Pexa-Vec and JX929 for efficient cancer treatment. With a Risk Rating Score of 30.8, SillaJen is dedicated to achieving sustainability and governance in its operations. Operating in both Korea and the United States, SillaJen is leading the way in ESG-focused biotechnology advancements.